Work

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Year: 2016

Type: article

Source: Blood

DOI: 10.1182/blood.v128.22.591.591

Authors: Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand P Jillella, Dale L. Bixby, Moshe Y Levy, Megan M. O'Meara, Phoenix Ho, Anthony S. Stein

Institutions: Massachusetts General Hospital, University of Alabama at Birmingham, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, Hackensack University Medical Center, Fred Hutch Cancer Center, Cleveland Clinic, Dana-Farber Cancer Institute, University of Utah, Huntsman Cancer Institute, Winship Cancer Institute, University of Michigan, Michigan Medicine, Baylor University Medical Center, Seagen (United States), City Of Hope National Medical Center, City of Hope

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559908363

FWCI: 8.425

Cites:

Cited by: 44

Related to: 10